GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Change In Receivables

OPHLY (Ono Pharmaceutical Co) Change In Receivables : $58 Mil (TTM As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Ono Pharmaceutical Co Change In Receivables?

Ono Pharmaceutical Co's change in receivables for the quarter that ended in Mar. 2025 was $112 Mil. It means Ono Pharmaceutical Co's Accounts Receivable declined by $112 Mil from Dec. 2024 to Mar. 2025 .

Ono Pharmaceutical Co's change in receivables for the fiscal year that ended in Mar. 2025 was $50 Mil. It means Ono Pharmaceutical Co's Accounts Receivable declined by $50 Mil from Mar. 2024 to Mar. 2025 .

Ono Pharmaceutical Co's Accounts Receivable for the quarter that ended in Mar. 2025 was $906 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Ono Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2025 was 109.70.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ono Pharmaceutical Co's liquidation value for the three months ended in Mar. 2025 was $491 Mil.

Ono Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Ono Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ono Pharmaceutical Co Change In Receivables Chart

Ono Pharmaceutical Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -66.05 -128.89 -108.58 -132.04 49.59

Ono Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.55 -44.06 80.41 -90.06 112.06

Ono Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ono Pharmaceutical Co  (OTCPK:OPHLY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ono Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=905.838/753.46*91
=109.70

2. In Ben Graham's calculation of liquidation value, Ono Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Ono Pharmaceutical Co's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1411.401-1850.587+0.75 * 905.838+0.5 * 502.249
=491

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ono Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Ono Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Change In Receivables
Comparable Companies
TSE:4536 TSE:4151 TSE:4552 TSE:4882 TSE:4503 TSE:4578 LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN PFE GILD XPAR:SAN BMY TSE:4519
Traded in Other Exchanges
OPHLF:USA 4528:Japan ON4:Germany
Address
8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564
Website
http://www.ono.co.jp
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a world-wide business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.